I have a teaching role within Barts Cancer Institute. I am the Module Lead for 3 undergraduate Biomedical Science Modules: Tissue Biology for Year 1, Cellular Pathology and Blood Science for Year 3 and the elective Year 3 module, Molecular Basis of Personalised Medicine. I am also the Cancer Theme Lead for MBBS with direct responsibility for Year 2 Cancer Week. In addition, I supervise MSc project dissertations.
EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedure. Rezvani K, Kanfer EJ, Marin D et al. Biol Blood Marrow Transplant (2012) 18(1) 235-240
Array-based DNA methylation profiling in follicular lymphoma O'Riain C, O'Shea DM, Yang Y et al. Leukemia (2009) 23(1) 1858-1866
Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts Le Dieu R, Taussig D, Ramsay AG et al. Blood (2009) 114(1) 3909-3916
Negative immunomagnetic selection of T cells from peripheral blood of presentation AML specimens Le Dieu R, Taussig D, Lister TA et al. Journal of Immunological Methods (2009) 348(1) 95-100
E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction Gorgun G, Ramsay AG, Holderried TAW et al. PNAS (2009) 106(1) 6250-6255
Transplantation in chronic lymphocytic leukemia Le Dieu R, Gribben JG Current Hematologic Malignancy Reports (2007) 2(1) 56-61
Major obstetric haemorrhage in late termination of pregnancy in eight women. Sekhar M, Narat S, Le Dieu R et al. BLOOD (2006) 108(3) 89B-90B
Allogeneic Stem Cell Transplantation for Non-Hodgkin's and Hodgkin's Lymphoma Le Dieu R, Gribben JG (2006) (1)
In vivo demonstration of donor idiotype specific T cells that kill primary CLL cells post allogeneic transplant Ledieu R, Gorgun G, Gribben J (2005) (1)
Homoharringtonine in combination with imatinib for patients with CML who have achieved partial or complete cytogenetic responses. Le Dieu R, Bua M, Andreasson C et al. BLOOD (2004) 104(3) 289A-289AFor additional publications, please click here
I am an Honorary Consultant at Barts Health NHS Trust where I have a lymphoma practice. I trained at St John’s College, Cambridge and Imperial College, London before completing Haematology specialist training in NW London. My subsequent research focused on the microenvironment in cancer and I completed a PhD and subsequent post-doctoral research in Professor John Gribben’s group.
Since joining Barts, I have taken an active interest in clinical trials and joined the NCRI Hodgkins Lymphoma subgroup. I speak at the Lymphoma Action Management Course on relapsed Hodgkin’s lymphoma.
I am a passionate advocate of flexible working for medical staff via my dual roles as Barts Health Champion of Flexible Working and Joint Deputy Director of the Royal College of Physicians’ Medical Workforce Unit.
Over the course of my medical career, I have developed a keen interest in teaching which my role at Barts Cancer Institute has allowed me to progress. I am particularly interested in new ways of delivering teaching and also cultivating good teachers.